Neural Plasticity

Neural Plasticity / 2012 / Article

Review Article | Open Access

Volume 2012 |Article ID 784040 |

Alessandra Berry, Erika Bindocci, Enrico Alleva, "NGF, Brain and Behavioral Plasticity", Neural Plasticity, vol. 2012, Article ID 784040, 9 pages, 2012.

NGF, Brain and Behavioral Plasticity

Academic Editor: Eero Castren
Received03 Oct 2011
Accepted06 Dec 2011
Published16 Feb 2012


Nerve Growth Factor (NGF) was initially studied for its role as a key player in the regulation of peripheral innervations. However, the successive finding of its release in the bloodstream of male mice following aggressive encounters and its presence in the central nervous system led to the hypothesis that variations in brain NGF levels, caused by psychosocial stressor, and the related alterations in emotionality, could be functional to the development of proper strategies to cope with the stressor itself and thus to survive. Years later this vision is still relevant, and the body of evidence on the role of NGF has been strengthened and expanded from trophic factor playing a role in brain growth and differentiation to a much more complex messenger, involved in psychoneuroendocrine plasticity.

1. Introduction

At the beginning of the 1950s, the Nobel Laureate Rita Levi-Montalcini discovered and characterized the Nerve Growth Factor (NGF) as a key player in target-mediated regulation of peripheral innervations [1, 2]. The pioneer studies performed by her and Victor Hamburger first showed that the nervous system requires an adequate supply of trophic factors (neurotrophins—NTs) from the environment for survival and development. In addition, and most intriguingly, these studies first raised the concept of cell death playing a pivotal role in this specific context. In particular, target tissues might determine the size and morphology of the peripheral innervations by regulating cell death among neurons and by making the NTs available only in limited amounts, finally resulting in the selection only of those neurons which have established the quantitative and qualitative numbers of connections (with the target tissue). Subsequent studies have demonstrated that, during nervous system development, NGF is released by the target tissue, taken up in responsive neurons by receptor-mediated endocytosis and transported retrogradely to the cell body where it exerts its trophic/differentiative effects through its low (p75NTR) and high affinity receptors (TrkA) [37]. In particular, while the p75NTR can cause apoptosis in a variety of systems, when coexpressed with TrkA, it can modify their ligand-binding activity, dose-responsiveness, and kinase activity, leading to increased survival, neurite outgrowth, and synaptic plasticity [812].

Since these first investigations on target-controlled neuronal survival, NGF has been one of the most thoroughly studied NTs, regulating the survival, development, and trophism of specific neuronal populations in the peripheral and central nervous system (CNS) [13]. While in the periphery this NT was first recognized for its action on the sympathetic ganglia, in the adult brain the highest levels of NGF are found in hippocampus, cortex, and olfactory regions, which represent targets for basal forebrain cholinergic neurons [14, 15]. NGF acts as a trophic factor for these neurons since its administration in vivo increases the levels of choline acetyltransferase [16, 17] while rescuing from death basal forebrain neurons following transection of the septo-hippocampal pathways [18]. In addition to the nervous system, NTs exert their effects on various other tissue compartments [1926]. The largest amount of NGF is produced in the salivary glands of adult male mice, which are the largest and best available source of this NT (smaller concentrations of this NT can be found in snake venom, guinea pig prostate, the seminal fluid of guinea pigs and bulls, in the human skin, and in numerous tissues and body fluids [13]). Furthermore, a number of other cells outside the nervous system, including epithelial cells, fibroblasts, lymphocytes, and activated macrophages, synthesize NGF [2729].

Since NGF discovery, no explanation was available for almost three decades on NGF physiological role in adult animals. Most neurobiologists, for a very long time, explained its presence in adult animals because of its ancestral physiological role during ontogeny. NGF was originally described as a protein exclusively acting on sympathetic peripheral neurons and only much later it was found to be also active on central nervous system neurons and on a variety of immune cell types [30]. Overall, the presence of NGF in those limbic areas of the CNS involved in mood and cognition and in the orchestration of neuroendocrine responses and circadian activities, as well as in cells of the immune and endocrine system, indicates a much wider role for this NT than previously hypothesized and suggests that it might function as intercellular messenger or even a humoral factor to help regulate endocrine responses to stress [19, 3135].

2. Stress Renewed CNS and Adrenal Plasticity

Stress may be defined as any change of the internal or external milieu perturbing the maintenance of homeostasis of an organism. In complex organisms, stress responses involve a coordinated set of intercellular signals eventually resulting in the removal of the organism from, or adaptation to, the stressful situation. Coping strategies are therefore important components of the stress response allowing an animal to “fright, fight or flight” [36]. Pivotal to these allostatic/adaptive responses is the neuroendocrine system that employs neuropeptides and hormones as mediators. The hypothalamic-pituitary-adrenal (HPA) axis (which releases the glucocorticoids—GCs—hormones) and sympathetic adrenomedullary systems (which releases catecholamines) coordinate the stress response. Although the cascade of responses to acute stressful events originates at the CNS level, peripheral structures, such as the adrenal glands, act in interplay and feedback on the brain to maintain body homeostasis [37, 38]. By contrast, chronic stress can promote and exacerbate pathophysiological conditions through these same systems, leading to allostatic overload [39]. The adaptive plasticity of chronic stress involves many mediators, including GCs, excitatory amino acids, and NTs, such as NGF and also Brain-Derived Neurotrophic Factor (BDNF). These latter can participate in the HPA axis response to stressful stimuli at different anatomical levels [38, 40].

In the wild, adult male mice exhibit high levels of intraspecific aggressive behavior towards conspecifics mainly related to territorial defense. In the laboratory setting, the agonistic behavior of male mice can be elicited after 4–6 weeks of social isolation and represents a psychosocial stressful condition that has been shown to markedly alter NGF and BDNF levels both in plasma as well as in selected brain areas, including the hypothalamus and hippocampus [41, 42]. In the mouse, NGF is mainly synthesized and released from the submaxillary salivary glands [5, 43]. Neurobehavioral studies demonstrated that both male intraspecific fighting and lactating females nest-defense, raised against a potentially infanticidal conspecific male, induce a massive release of NGF from salivary glands into the bloodstream of adults. In particular, circulating levels of NGF are highly correlated with the number of fighting episodes and most intriguingly to the social status achieved in fighting mice. Thus, subjects experiencing repeated defeat and submissions (i.e., a subordinate status) were characterized by a two-time increase in the amount of circulating NGF compared to attacking mice that achieved a dominant status [44, 45]. In this specific context it is worth to note that physical stressors, such as cold water, foot shocks, or restraint stress exposure, exert a minor effect on NGF release [43, 46].

Following fighting behavior, adrenal weight increases quite markedly and quickly in male mice suggesting that social/aggressive behavior might control circulating NGF release from salivary glands and that these might in turn control adrenal morphology as well as adrenal functional status [47, 48]. This hypothesis has been supported by data showing that exogenous NGF administration (i.p. delivery, for 10 consecutive days in order to mimic 10 subsequent daily fighting sessions) results in a marked adrenal gland hypertrophy [43, 47, 48]. Thus, NGF release may exert an inhibitory feedback effect on aggressive behavior. The higher NGF release and the hypertrophy of the adrenals, occurring in subordinates male mice, suggest a “regulative loop” involving NGF-mediated increase of glucocorticoids secretion (upon adrenals) acting to enhance a submissive profile (Figure 1) [46, 47, 49].

Further experimental evidence supports the idea that NGF expression may be regulated by behavioral activation. In particular, intermale aggressive behavior induces a large increase in NGF mRNA and protein in hypothalamus, especially in the paraventricular nucleus, with no measurable changes in cerebral cortex, hippocampus, and cerebellum [50]. The increase in hypothalamic NGF following intermale aggressive behavior is not abolished by sialoadenectomy, suggesting that hypothalamic NGF is not of salivary origin [43]. Alleva and Aloe hypothesized that the rather rapid increase in levels of brain NGF, which follows a psychosocial stressful event, could allow some renewal of brain plasticity at adulthood [46].

Indeed, NGF could contribute to structural changes, such as the formation of dendritic spines or collateral sprouting, ultimately altering the structure of neural connections in the mature brain [46, 47]. Another possibility is that hypothalamic NGF might affect levels of other peptides or hormones present in the hypothalamus [5155]. Taken together, these studies suggest that hypothalamic NGF levels are responsive to (and modified by) stimuli of a psychological nature, most likely associated with anxiety and fear. As hypothalamus is involved in the maintenance of physiological homeostasis, it is likely that hypothalamic NGF affects, or cooperates with, hormones and/or neurotransmitters present in this brain area to ultimately integrate behavioral and neuroendocrine responses [31, 46].

In this complex scenario, peripheral organs, such as adrenal glands, might be seen as remote CNS stations able to regulate behavioral reactivity. Such an “extremely peripheral” location provides most of the body with a remote station, in strict hormonal connection with some functionally integrated brain zones, to easily and efficaciously control the entire organisms. In addition and more importantly, these glands are morphologically (and functionally) endowed with a very high degree of plasticity leading to profound endocrine and behavioral modifications, and both short-term changes in behavioral reactivity at the individual level and changes in mouse population structure (e.g., major behavioral changes in reactivity to social stimulation) could be expected [43, 5659]. Thus, NGF appears to play a role in stress-mediated changes in behavioral responses, leading to imprinting-like phenomena at adulthood, in which such social stimuli suddenly become relevant and produced long-lasting behavioral alterations. In particular, it could be hypothesized that variations in the hypothalamic NGF, caused by psychosocial stressor, and the related alterations in emotionality, could be functional to the development of proper strategies to cope with the stressor itself and thus to survive. NGF could shift some still unknown brain zones backwards to an “immature-like” stage [46, 49].

3. The Role of NGF at the Peripheral Level

Belonging to the neuroendocrine system, the anterior pituitary gland represents an important relay station between the periphery and the CNS under the control of hypothalamic hormones and peripheral signals. The integration operated by this gland determines the extent of hormonal secretion in different physiological situation and NGF and BDNF appear to play a neurotrophic role on the pituitary and stimulate synthesis of neuropeptides. The first evidence of such a role for NTs came from studies suggesting that, following intravenous injection, NGF increased the secretion of adrenocorticotropic hormone (ACTH) as well as the concentration of GCs, and that following a psychosocial stress, a massive release of NGF occurred in the peripheral circulation, associated with increased hypothalamic NGF mRNA and protein levels [43, 60, 61].

NGF is synthesized in the granular convoluted tubules within the submandibular glands soon after puberty (much more in male than in female subjects) [5, 13]. The functional significance of the large amounts of NGF observed in the mouse submandibular glands is not fully elucidated; however it has been shown to be released into the bloodstream as a result of intraspecific aggressive behavior acting on nerve, chromaffin, mast cells, and lymphocytes [43, 61, 62]. The adrenal glands are intrinsically characterized by a high degree of plasticity from a morphological (and functional) point of view [43]. Their size varies according to short- and medium-term life stressful events, and such a morpho-functional change is mirrored by subtle and rapid central modification in the expression of the hippocampal glucocorticoids receptor (GR) system, in the excitability of hippocampal neurons, neurogenesis of the dentate gyrus, synaptogenesis in the CA1 region, and dendritic remodeling in the CA3 region, just to mention few [63]. NGF appears as key player in the ontogeny of adrenal glands as its administration induces the transformation of chromaffin cells in sympathetic nerve cells in the adrenal medulla. By contrast, injections of NGF antiserum (from prenatal day 17 to postnatal day 10 in rats) inhibit adrenal development and differentiation through a massive destruction of chromaffin cell precursors [64] overall showing the main role played by NGF in critical developmental stages [37, 38].

Thus adrenal glands can be viewed as representing the last pair of vertebral ganglia. During early (in altricial rodents late-gestational) developmental stages, thanks to a complex interaction of neurohormonal factors (including GCs and NGF, as reported just below), they do not fully differentiate as adult-like ganglia but maintain several fetal-type characteristics. Therefore, their enhanced morphofunctional plasticity is maintained through adulthood, rendering them a remote (control) neurohormonal station involved in a continuous dialog with the brain for the maintenance of body homeostasis [37, 38].

A large body of evidence suggests a link between adrenal size modification and coping strategies to face stressful events which might underlie the association often found for a pathologic increase in corticosteroid hormones and vulnerability to psychiatric disorders [46]. Since the adrenal gland appears to be one of the biological targets of NGF, one way this growth factor could exert a physiologic role is through its action on this structure. NGF administered for 6–10 consecutive days results in a dose-dependent increase in adrenal weight and volume by enlarging both the adrenal medulla and the cortex [43, 49]. At present, it is not clear whether adrenal cortex hypertrophy following NGF administration in adult mice is the result of a direct action of this NT on adrenal cortex cells or whether it is mediated through its effects on ACTH release. Interestingly, it has been shown that conditions exist in which adrenal activity is uncoupled from ACTH, such as during starvation [65], and this suggests a direct effect of NGF on the adrenals under specific conditions. Furthermore, in animal models characterized by metabolic disorders involving dysregulation of the HPA axis, such as type I diabetes, corticosterone hypersecretion appears to occur independently from a surge in ACTH levels [38, 66]. NGF might also contribute as an alternative mechanism in inducing such rapid changes in adrenal sensitivity. Changes in adrenal hormone secretion (e.g., increased corticosterone levels) resulting from an increase in NGF circulating levels could exert important effects on aggressive behavior: GCs enhance aggressive behavior in a context-dependent fashion, promoting social challenge-induced aggression without increasing aggressiveness under routine conditions in rats [67, 68]. Indeed, at present, there is no evidence of direct NGF effects on neural substrates of aggressive behavior, and the high molecular weight of the NGF protein seems to exclude the possibility that it could cross the blood-brain barrier, although a possible breakage of the NGF protein into fragments acting on the CNS can be postulated [69]. From a clinical application point of view, it appears interesting to point out that successful transport of biologically active NGF across the blood-brain barrier has been achieved by covalently linking it to an antitransferrin receptor antibody or by ocular delivery [38, 70, 71]. Likewise, Aloe and Alleva, working in the team of Levi-Montalcini, analyzed all the evidences collected up to that point on the physiological activities exerted by NGF on CNS and non-CNS neurons [31]. In those years, starting with mast cells [72, 73], and much later memory B lymphocytes [74], evidences were provided for a role of NGF on psychoneuroimmune regulation [31, 46].

4. The Role of NGF at the CNS

Most of the studies on NGF were originally performed by Rita-Levi Montalcini on the sympathetic ganglia explanted from chick embryos [5, 75], leading to an initial fascinating but incomplete vision of NGF as a protein molecule exerting specific—although limited—effects on peripheral sympathetic neurons. Further studies, carried out, rather independently by Barde and Thoenen, and Mobley, characterized NGF effects on cholinergic neurons at the CNS level, opening the way to several lines of research aimed at understanding NGF physiological roles in the brain [7, 12, 76].

NGF is essential for the development and maintenance of sensory neurons, and for the formation of central pain circuitry, exogenous administration of this neurotrophin to rodents resulting in the rapid onset of hyperalgesia [69]. Together with its receptors (p75 and TrkA), it plays a critical trophic role on forebrain cholinergic neurons (FCNs) that degenerate during brain aging and neurodegenerative disorders [77, 78]. During development, both NGF and BDNF regulate naturally occurring cell death, synaptic connectivity, fiber guidance, and dendritic morphology [79]. Furthermore, they participate to brain plasticity, being involved in activity-dependent neuronal functions [34, 7981]. During early postnatal development, especially during critical periods, large changes in the connectivity and organization of neural networks take place [82, 83]. In this period, the developing CNS is particularly sensitive to external stimuli, and NGF and BDNF play a key role in modulating brain plasticity to better cope with environmental stimuli. As an example, mice reared in a communal nest (CN, which consists in a single nest where three mothers keep their pups together and share care-giving behavior from birth to weaning) are characterized by increased NGF and BDNF levels in selected brain areas, including hippocampus and hypothalamus, and prolonged survival of newly generated cells in the hippocampus. These features possibly underly the higher propensity of CN mice to interact socially and their better social skills when compared to subjects reared in standard laboratory conditions [84, 85]. The adult brain still shows significant plasticity: for example, repeated agonistic intermale fighting in aged mouse selectively affects neurotrophin production. In particular, the social stress of being subordinate is able to increase NGF levels in the Subventricular Zone (SVZ) and hippocampus (a brain area involved in learning and memory processes) leading to the hypothesis of a regulatory role of NGF in the “emotional” status caused by psychosocial stressors and the physiological needs of the organism to “remember” the events leading to an appropriate coping with the stressor itself [41, 47]. Moreover, aggressive behavior can enhance the number of Ki67-positive cells in the SVZ of aged animals. This suggests that, in the aged mouse, fighting behavior may increase neurogenesis, most probably throughout proliferation and/or differentiation of brain stem cells [86], possibly contributing to reduce the neuronal damage and loss caused by prolonged GC exposure as a consequence of the social stress related to fighting [87, 88]. In addition, within the brain, the major increase in NGF following fighting has been observed in the hypothalamus a brain area involved in the activation of certain behaviors and in physiological modifications inducing changes in bodily homeostasis, suggesting a role for NGF in coping and neuroendocrine mechanisms [31].

A correlation between changes in NGF levels and anxiety-like behaviors has been observed in humans. In particular, NGF levels were found to be increased in the blood of young soldiers experiencing their first parachute jump, implying that the release of NGF in the bloodstream is triggered by the stress of the novel and highly arousing experience [62]. The key role of NGF in anxiety conditions is also suggested by findings demonstrating that alcohol or heroin withdrawal in human is also associated to changes in blood NGF levels [89].

Chronicity of stress system activation leads to the syndromal state that in 1936 Selye described as the “general adaptation syndrome” [90]. When facing a stressful situation, all physiological changes, related to coping strategies, lead both to protective and damaging effects on the body. In particular, on a short run they are essential for adaptation, maintenance of homeostasis, and survival (allostasis is maintaining stability through changes). Yet, over longer time intervals, they impose a cost (allostatic load) that can accelerate disease processes or participate to pathological changes possibly contributing to the development of neurodegenerative disorders and/or to precipitate psychopathological conditions [91].

NGF, both in the bloodstream and in certain brain areas, is differentially expressed following environmental stressors. A large number of evidence show that chronic stress can lead to anxiety- and depression-like behaviors and may influence the distribution of NGF, both in animal models and in humans [46, 92]. Reduced NGF and BDNF signaling in the adult brain may be involved in the pathophysiology of psychiatric disorders, such as depression [38, 81, 9396], and a role for NGF has been proposed in the etiopathogenesis of schizophrenia [97].

NTs themselves do not directly affect mood but rather play an important functional role in the modulation of networks determining how plastic changes influences mood [94]. In fact, it has been hypothesized that, by activating NTs systems, successful antidepressant treatments and cotreatments promote activity-dependent neuronal plasticity, possibly inducing proliferative or survival effects on neural stem cells [81]. Because of the fundamental role played by these neurotrophic factors in shaping brain function, pathological alterations in their concentration or action early during development could exert long-term effects on synaptic plasticity, impairing the ability of the organism to cope with novel/stressful situations, leading to psychopathology [98]. During development, the expression of NGF and BDNF has been localized to the hippocampus and prefrontal cortex, two regions which are well-studied sites of both developmental and adult synaptic plasticity and playing a key role in psychiatric disorders [15, 99].

Stress during prenatal and early postnatal life may result in altered brain development and lead to a persistent sensitization of limbic circuits to even mild stress at adulthood, forming the basis for a greater susceptibility for mood and anxiety disorders (Levine, 1967 no.49; Maccari, 2003 no.117). Numerous studies performed in rodents have indicated that NTs are sensitive to the stress of maternal separation and to changes in the rearing conditions and that environmental stimulation can have both short- and long-term effects on NTs levels [84, 100107]. It is possible to hypothesize that while milder manipulations could promote neural plasticity, chronic stressful conditions could sensitize limbic structures to stress, decreasing brain plasticity and leading to higher susceptibility to psychopathology [102, 108]. As an example, in rodents, separating mother and infant for brief periods results in increased NGF expression in the hippocampus, cerebral cortex, and hypothalamus in a time-dependent manner [101, 104] while longer periods of maternal separation (24 h) also result in increased rate of cell death in the neocortex, white matter, and granule cells of the dentate gyrus in 12-day-old rats [109]. Following chronic communal nesting increased BDNF levels in association with reduced neurogenesis and increased depression-like behavior have been also found in CD-1 mice [84].

Epidemiological studies indicate that anxiety and mood disorders are characterized by sex differences in prevalence, presentation or therapeutic outcomes. A recent study suggests that epigenetic changes, presumably in the male germ cells, might alter the exposure to the hormones that mediate brain masculinization, providing insight into the heritability and pathophysiology of sex-biased neurodevelopmental disorders [110]. In addition, a very interesting work from Cirulli and collaborators provides evidence for a specific role of NTs in such a gender-specific vulnerability. In particular, BDNF and NGF were identified as neuroendocrine markers underlying differential responses to maternal deprivation in males and females rhesus macaques. The selective changes in BDNF levels in females suggest a possible mechanism for the greater vulnerability to mood disorders of this gender as reported in humans [103].

The importance of early life experiences in the etiology of psychiatric disorders has been now recognized; however it has been often underemphasized. Early life stressful events, such as childhood trauma and neglect, are associated with depression and anxiety disorders and sustained changes in the HPA axis [111113]. These associations strengthen the hypothesis that environmental factors during development could lead to long-term enduring changes in the set-point of the neuroendocrine system physiology and emotional behavior.

Changes in the levels of NGF in the CNS appear also to play an important role in the context of neurodegenerative disorders such as Alzheimer disease (AD). The disruption of NGF gene in transgenic mice leads to a lethal phenotype; thus only the study of phenotypic knockout of NGF at adulthood is possible [114]. Transgenic mice expressing a neutralizing anti-NGF recombinant antibody are characterized by an age-dependent neurodegenerative pathology including amyloid plaques, insoluble and hyperphosphorylated tau, and neurofibrillary tangles in cortical and hippocampal neurons. Furthermore, they show an extensive neuronal loss throughout the cortex, cholinergic deficit in the basal forebrain in addition to behavioral deficits, overall being strikingly reminiscent of human AD [115]. NGF precursor (pro-NGF) has been shown to be highly expressed in the brains of AD patients and to be neurotoxic when bound in a heterotrimer with the p75 and the receptor sortilin. Interestingly, sortilin levels are increased in aged central and peripheral neurons, possibly rendering neurons more vulnerable to the age-related increases in pro-NGF [116]. More recently, Capsoni and coworkers postulated that neurodegeneration occurring in a transgenic mouse model of AD is provoked by an imbalance of proNGF/NGF and, consequently, of TrkA/p75 signaling such that the inactivation of TrkA determines a strong cholinergic deficit and AD-like neurodegeneration [117]. Thus, overall, the NGF/TrkA signaling pathway has emerged as a promising therapeutic target for the AD pathology [118].

In addition to a possible therapeutic role in the context of neurodegenerative disorders, Chiaretti and coworkers investigated the role of NGF in regard to severe traumatic brain injury (TBI) in pediatric patients [119]. TBI is the most common cause of death and acquired disability among children and young adults in developed countries and its clinical outcome depends both or the primary cerebral lesions and or the extent of secondary brain damage which involves neuroinflammatory mechanisms. It has been suggested that interleukin-6 might participate to the mechanisms of recovery from TBI through the modulation of NGF biosynthesis, elevated levels of this neurotrophin representing a reliable marker of good prognosis, at least in children [119]. Moreover, and more recently, the same authors proposed that NGF might represent an effective and safe adjunct therapy in patients (children and adults) with severe hypoxicischemic injury suggesting a neuroprotective mechanism exerted by NGF on the residual viable neurological pathways of these patients [120].


E. Alleva received funding support from the Italian Ministry of Health, project NIH-ISS Rif. 530F/51. The authors are grateful to N. Francia and L.T. Bonsignore for their skillful help in retrieving and selecting bibliographic entries.


  1. V. Hamburger and R. Levi-Montalcini, “Proliferation, differentiation and degeneration in the spinal ganglia of the chick embryo under normal and experimental conditions,” Journal of Experimental Zoology, vol. 111, no. 3, pp. 457–501, 1949. View at: Google Scholar
  2. R. Levi-Montalcini and V. Hamburger, “Selective growth stimulating effects of mouse sarcoma on the sensory and sympathetic nervous system of the chick embryo,” Journal of Experimental Zoology, vol. 116, no. 2, pp. 321–361, 1951. View at: Google Scholar
  3. M. Barbacid, F. Lamballe, D. Pulido, and R. Klein, “The trk family of tyrosine protein kinase receptors,” Biochimica et Biophysica Acta, vol. 1072, no. 2-3, pp. 115–127, 1991. View at: Google Scholar
  4. I. A. Hendry, K. Stockel, H. Thoenen, and L. L. Iversen, “The retrograde axonal transport of nerve growth factor,” Brain Research, vol. 68, no. 1, pp. 103–121, 1974. View at: Publisher Site | Google Scholar
  5. R. Levi-Montalcini, “The nerve growth factor 35 years later,” Science, vol. 237, no. 4819, pp. 1154–1162, 1987. View at: Google Scholar
  6. S. O. Meakin and E. M. Shooter, “The nerve growth factor family of receptors,” Trends in Neurosciences, vol. 15, no. 9, pp. 323–331, 1992. View at: Publisher Site | Google Scholar
  7. H. Thoenen and Y. A. Barde, “Physiology of nerve growth factor,” Physiological Reviews, vol. 60, no. 4, pp. 1284–1335, 1980. View at: Google Scholar
  8. G. L. Barrett, “The p75 neurotrophin receptor and neuronal apoptosis,” Progress in Neurobiology, vol. 61, no. 2, pp. 205–229, 2000. View at: Publisher Site | Google Scholar
  9. M. V. Chao and M. Bothwell, “Neurotrophins: to cleave or not to cleave,” Neuron, vol. 33, no. 1, pp. 9–12, 2002. View at: Publisher Site | Google Scholar
  10. G. Dechant and Y. A. Barde, “The neurotrophin receptor p75NTR: novel functions and implications for diseases of the nervous system,” Nature Neuroscience, vol. 5, no. 11, pp. 1131–1136, 2002. View at: Publisher Site | Google Scholar
  11. F. D. Miller and D. R. Kaplan, “On Trk for retrograde signaling,” Neuron, vol. 32, no. 5, pp. 767–770, 2001. View at: Publisher Site | Google Scholar
  12. H. Thoenen, C. Bandtlow, and R. Heumann, “The physiological function of nerve growth factor in the central nervous system: comparison with the periphery,” Reviews of Physiology Biochemistry and Pharmacology, vol. 109, pp. 145–178, 1987. View at: Google Scholar
  13. R. Levi-Montalcini and P. U. Angeletti, “Nerve growth factor,” Physiological Reviews, vol. 48, no. 3, pp. 534–569, 1968. View at: Google Scholar
  14. S. Korsching, G. Auburger, R. Heumann, J. Scott, and H. Thoenen, “Levels of nerve growth factor and its mRNA in the central nervous system of the rat correlate with cholinergic innervation,” EMBO Journal, vol. 4, no. 6, pp. 1389–1393, 1985. View at: Google Scholar
  15. T. H. Large, S. C. Bodary, D. O. Clegg, G. Weskamp, U. Otten, and L. F. Reichardt, “Nerve growth factor gene expression in the developing rat brain,” Science, vol. 234, no. 4774, pp. 352–355, 1986. View at: Google Scholar
  16. H. Gnahn, F. Hefti, R. Heumann, M. E. Schwab, and H. Thoenen, “NGF-mediated increase of choline acetyltransferase (ChAT) in the neonatal rat forebrain: evidence for a physiological role of NGF in the brain?” Brain Research, vol. 285, no. 1, pp. 45–52, 1983. View at: Google Scholar
  17. W. C. Mobley, J. L. Rutkowski, G. I. Tennekoon, K. Buchanan, and M. V. Johnston, “Choline acetyltransferase activity in striatum of neonatal rats increased by nerve growth factor,” Science, vol. 229, no. 4710, pp. 284–287, 1985. View at: Google Scholar
  18. S. Korsching, R. Heumann, H. Thoenen, and F. Hefti, “Cholinergic denervation of the rat hippocampus by fimbrial transection leads to a transient accumulation of nerve growth factor (NGF) without change in mRNA(NGF) content,” Neuroscience Letters, vol. 66, no. 2, pp. 175–180, 1986. View at: Google Scholar
  19. L. Aloe, L. Bracci-Laudiero, S. Bonini, and L. Manni, “The expanding role of nerve growth factor: from neurotrophic activity to immunologic diseases,” Allergy, vol. 52, no. 9, pp. 883–894, 1997. View at: Google Scholar
  20. L. Aloei, L. Manni, G. Sebastiani, and M. A. Tuveri, “Nerve growth factor in the synovia of patients with rheumatoid arthritis: correlation with TNF-α and IL-1β and possible functional significance,” Clinical and Experimental Rheumatology, vol. 17, no. 5, pp. 632–633, 1999. View at: Google Scholar
  21. E. Dicou, J. Lee, and P. Brachet, “Synthesis of nerve growth factor mRNA and precursor protein in the thyroid and parathyroid glands of the rat,” Proceedings of the National Academy of Sciences of the United States of America, vol. 83, no. 18, pp. 7084–7088, 1986. View at: Google Scholar
  22. M. Hadjiconstantinou, L. McGuire, A. M. Duchemin, B. Laskowski, J. Kiecolt-Glaser, and R. Glaser, “Changes in plasma nerve growth factor levels in older adults associated with chronic stress,” Journal of Neuroimmunology, vol. 116, no. 1, pp. 102–106, 2001. View at: Publisher Site | Google Scholar
  23. R. Katoh-Semba, R. Semba, S. Kashiwamata, and K. Kato, “Sex-dependent and sex-independent distribution of the β-subunit of nerve growth factor in the central nervous and peripheral tissues of mice,” Journal of Neurochemistry, vol. 52, no. 5, pp. 1559–1565, 1989. View at: Google Scholar
  24. J. Lakshmanan, “Nerve growth factor levels in mouse serum: variations due to stress,” Neurochemical Research, vol. 12, no. 4, pp. 393–397, 1987. View at: Google Scholar
  25. E. Nisoli, C. Tonello, M. Benarese, P. Liberini, and M. O. Carruba, “Expression of nerve growth factor in brown adipose tissue: implications for thermogenesis and obesity,” Endocrinology, vol. 137, no. 2, pp. 495–503, 1996. View at: Publisher Site | Google Scholar
  26. U. Raap, N. Deneka, M. Bruder, A. Kapp, and B. Wedi, “Differential up-regulation of neurotrophin receptors and functional activity of neurotrophins on peripheral blood eosinophils of patients with allergic rhinitis, atopic dermatitis and nonatopic subjects,” Clinical and Experimental Allergy, vol. 38, no. 9, pp. 1493–1498, 2008. View at: Publisher Site | Google Scholar
  27. I. Gozes, D. T. O'Connor, and F. E. Bloom, “A possible high molecular weight precursor to vasoactive intestinal polypeptide sequestered into pheochromocytoma chromaffin granules,” Regulatory Peptides, vol. 6, no. 2, pp. 111–119, 1983. View at: Publisher Site | Google Scholar
  28. C. E. Bandtlow, R. Heumann, M. E. Schwab, and H. Thoenen, “Cellular localization of nerve growth factor synthesis by in situ hybridization,” EMBO Journal, vol. 6, no. 4, pp. 891–899, 1987. View at: Google Scholar
  29. D. Lindholm, R. Heumann, M. Meyer, and H. Thoenen, “Interleukin-1 regulates synthesis of nerve growth factor in non-neuronal cells of rat sciatic nerve,” Nature, vol. 330, no. 6149, pp. 658–659, 1987. View at: Google Scholar
  30. I. B. Black, “Trophic molecules and evolution of the nervous system,” Proceedings of the National Academy of Sciences of the United States of America, vol. 83, no. 21, pp. 8249–8252, 1986. View at: Google Scholar
  31. R. Levi-Montalcini, L. Aloe, and E. Alleva, “A role for nerve growth factor in nervous, endocrine and immune systems,” Progress in Neuroendocrinoimmunology, vol. 3, pp. 1–10, 1990. View at: Google Scholar
  32. G. N. Chaldakov, M. Fiore, M. G. Hristova, and L. Aloe, “Metabotrophic potential of neurotrophins: implication in obesity and related diseases?” Medical Science Monitor, vol. 9, no. 10, pp. HY19–HY21, 2003. View at: Google Scholar
  33. M. Hristova and L. Aloe, “Metabolic syndrome—neurotrophic hypothesis,” Medical Hypotheses, vol. 66, no. 3, pp. 545–549, 2006. View at: Publisher Site | Google Scholar
  34. M. A. Smith, S. Makino, S. Y. Kim, and R. Kvetnansky, “Stress increases brain-derived neurotropic factor messenger ribonucleic acid in the hypothalamus and pituitary,” Endocrinology, vol. 136, no. 9, pp. 3743–3750, 1995. View at: Publisher Site | Google Scholar
  35. J. I. W. Marketon and R. Glaser, “Stress hormones and immune function,” Cellular Immunology, vol. 252, no. 1-2, pp. 16–26, 2008. View at: Publisher Site | Google Scholar
  36. G. P. Chrousos and P. W. Gold, “The concepts of stress and stress system disorders: overview of physical and behavioral homeostasis,” Journal of the American Medical Association, vol. 267, no. 9, pp. 1244–1252, 1992. View at: Publisher Site | Google Scholar
  37. E. Alleva and N. Francia, “Psychiatric vulnerability: suggestions from animal models and role of neurotrophins,” Neuroscience and Biobehavioral Reviews, vol. 33, no. 4, pp. 525–536, 2009. View at: Publisher Site | Google Scholar
  38. F. Cirulli and E. Alleva, “The NGF saga: from animal models of psychosocial stress to stress-related psychopathology,” Frontiers in Neuroendocrinology, vol. 30, no. 3, pp. 379–395, 2009. View at: Publisher Site | Google Scholar
  39. B. S. McEwen, “Physiology and neurobiology of stress and adaptation: central role of the brain,” Physiological Reviews, vol. 87, no. 3, pp. 873–904, 2007. View at: Publisher Site | Google Scholar
  40. A. Berry, V. Bellisario, S. Capoccia et al., “Social deprivation stress is a triggering factor for the emergence of anxiety-and depression-like behaviours and leads to reduced brain BDNF levels in C57BL/6J mice,” Psychoneuroendocrinology. In press. View at: Publisher Site | Google Scholar
  41. E. Alleva, L. Aloe, and S. Bigi, “An updated role for nerve growth factor in neurobehavioural regulation of adult vertebrates,” Reviews in the Neurosciences, vol. 4, no. 1, pp. 41–62, 1993. View at: Google Scholar
  42. E. Alleva, S. Petruzzi, F. Cirulli, and L. Aloe, “NGF regulatory role in stress and coping of rodents and humans,” Pharmacology Biochemistry and Behavior, vol. 54, no. 1, pp. 65–72, 1996. View at: Publisher Site | Google Scholar
  43. L. Aloe, E. Alleva, A. Bohm, and R. Levi-Montalcini, “Aggressive behavior induces release of nerve growth factor from mouse salivary gland into the bloodstream,” Proceedings of the National Academy of Sciences of the United States of America, vol. 83, no. 16, pp. 6184–6187, 1986. View at: Google Scholar
  44. E. Alleva, L. Aloe, F. Cirulli, D. D. Seta, and P. Tirassa, “Serum NGF levels increase during lactation and following maternal aggression in mice,” Physiology and Behavior, vol. 59, no. 3, pp. 461–466, 1996. View at: Publisher Site | Google Scholar
  45. D. Maestripieri, R. de Simone, L. Aloe, and E. Alleva, “Social status and nerve growth factor serum levels after agonistic encounters in mice,” Physiology and Behavior, vol. 47, no. 1, pp. 161–164, 1990. View at: Publisher Site | Google Scholar
  46. E. Alleva and L. Aloe, “Physiological roles of NGF in adult rodents: a biobehavioral perspective,” International Journal of Comparative Psychology, vol. 2, pp. 213–230, 1989. View at: Google Scholar
  47. E. Alleva and D. Santucci, “Psychosocial vs. “physical” stress situations in rodents and humans: role of neurotrophins,” Physiology and Behavior, vol. 73, no. 3, pp. 313–320, 2001. View at: Publisher Site | Google Scholar
  48. I. Branchi, N. Francia, and E. Alleva, “Epigenetic control of neurobehavioural plasticity: the role of neurotrophins,” Behavioural Pharmacology, vol. 15, no. 5-6, pp. 353–362, 2004. View at: Google Scholar
  49. S. Bigi, D. Maestripieri, L. Aloe, and E. Alleva, “NGF decreases isolation-induced aggressive behavior, while increasing adrenal volume, in adult male mice,” Physiology and Behavior, vol. 51, no. 2, pp. 337–343, 1992. View at: Publisher Site | Google Scholar
  50. M. G. Spillantini, L. Aloe, E. Alleva, R. de Simone, M. Goedert, and R. Levi-Montalcini, “Nerve growth factor mRNA and protein increase in hypothalamus in a mouse model of aggression,” Proceedings of the National Academy of Sciences of the United States of America, vol. 86, no. 21, pp. 8555–8559, 1989. View at: Google Scholar
  51. U. Otten, “Nerve growth factor and the peptidergic sensory neurons,” Trends in Pharmacological Sciences, vol. 5, pp. 307–310, 1984. View at: Google Scholar
  52. D. J. Albert, E. M. Dyson, M. L. Walsh, and B. B. Gorzalka, “Intermale social aggression in rats: suppression by medial hypothalamic lesions independently of enhanced defensiveness or decreased testicular testosterone,” Physiology and Behavior, vol. 39, no. 6, pp. 693–698, 1987. View at: Google Scholar
  53. L. Aloe and R. Levi-Montalcini, “Comparative studies on testosterone and L-thyroxine effects on the synthesis of nerve growth factor in mouse submaxillary salivary glands,” Experimental Cell Research, vol. 125, no. 1, pp. 15–22, 1980. View at: Google Scholar
  54. L. W. Swanson and P. E. Sawchenko, “Hypothalamic integration: organization of the paraventricular and supraoptic nuclei,” Annual Review of Neuroscience, vol. 6, pp. 269–324, 1983. View at: Google Scholar
  55. D. Wion, P. Barrand, E. Dicou, J. Scott, and P. Brachet, “Serum and thyroid hormones T3 and T4 regulate nerve growth factor mRNA levels in mouse L cells,” FEBS Letters, vol. 189, no. 1, pp. 37–41, 1985. View at: Publisher Site | Google Scholar
  56. D. Benton, J. F. Goldsmith, L. Gamal-el-Din, P. F. Brain, and F. H. Hucklebridge, “Adrenal activity in isolated mice and mice of different social status,” Physiology and Behavior, vol. 20, no. 4, pp. 459–464, 1978. View at: Publisher Site | Google Scholar
  57. P. F. Brain, “Mammalian behavior and the adrenal cortex. A review,” Behavioral Biology, vol. 7, no. 4, pp. 453–477, 1972. View at: Google Scholar
  58. S. Levine, “Maternal and environmental influences on the adrenocortical response to stress in weanling rats,” Science, vol. 156, no. 3772, pp. 258–260, 1967. View at: Google Scholar
  59. S. Levine, “Primary social relationships influence the development of the hypothalamic-pituitary-adrenal axis in the rat,” Physiology and Behavior, vol. 73, no. 3, pp. 255–260, 2001. View at: Publisher Site | Google Scholar
  60. U. Otten, J. B. Baumann, and J. Girard, “Stimulation of the pituitary-adrenocortical axis by nerve growth factor,” Nature, vol. 282, no. 5737, pp. 413–414, 1979. View at: Google Scholar
  61. L. Aloe, E. Alleva, and R. de Simone, “Changes of NGF level in mouse hypothalamus following intermale aggressive behaviour: biological and immunohistochemical evidence,” Behavioural Brain Research, vol. 39, no. 1, pp. 53–61, 1990. View at: Publisher Site | Google Scholar
  62. L. Aloe, L. Bracci-Laudiero, E. Alleva, A. Lambiase, A. Micera, and P. Tirassa, “Emotional stress induced by parachute jumping enhances blood nerve growth factor levels and the distribution of nerve growth factor receptors in lymphocytes,” Proceedings of the National Academy of Sciences of the United States of America, vol. 91, no. 22, pp. 10440–10444, 1994. View at: Publisher Site | Google Scholar
  63. B. S. McEwen, “Stress and hippocampal plasticity,” Annual Review of Neuroscience, vol. 22, pp. 105–122, 1999. View at: Publisher Site | Google Scholar
  64. L. Aloe and R. Levi-Montalcini, “Nerve growth factor-induced transformation of immature chromaffin cells in vivo into sympathetic neurons: effect of antiserum to nerve growth factor,” Proceedings of the National Academy of Sciences of the United States of America, vol. 76, no. 3, pp. 1246–1250, 1979. View at: Google Scholar
  65. M. F. Dallman, S. F. Akana, S. Bhatnagar et al., “Starvation: early signals, sensors, and sequelae,” Endocrinology, vol. 140, no. 9, pp. 4015–4023, 1999. View at: Google Scholar
  66. Y. Revsin, D. van Wijk, F. E. Saravia, M. S. Oitzl, A. F. de Nicola, and E. R. de Kloet, “Adrenal hypersensitivity precedes chronic hypercorticism in streptozotocin-induced diabetes mice,” Endocrinology, vol. 149, no. 7, pp. 3531–3539, 2008. View at: Publisher Site | Google Scholar
  67. J. Haller, S. Millar, J. V. J. van de Schraaf, R. E. de Kloet, and M. R. Kruk, “The active phase-related increase in corticosterone and aggression are linked,” Journal of Neuroendocrinology, vol. 12, no. 5, pp. 431–436, 2000. View at: Publisher Site | Google Scholar
  68. E. Mikics, B. Barsy, and J. Haller, “The effect glucocorticoids on aggressiveness in established colonies of rats,” Psychoneuroendocrinology, vol. 32, no. 2, pp. 160–170, 2007. View at: Publisher Site | Google Scholar
  69. Y. O. Taiwo, J. D. Levine, R. M. Burch, J. E. Woo, and W. C. Mobley, “Hyperalgesia induced in the rat by the amino-terminal octapeptide of nerve growth factor,” Proceedings of the National Academy of Sciences of the United States of America, vol. 88, no. 12, pp. 5144–5148, 1991. View at: Publisher Site | Google Scholar
  70. V. di Fausto, M. Fiore, P. Tirassa, A. Lambiase, and L. Aloe, “Eye drop NGF administration promotes the recovery of chemically injured cholinergic neurons of adult mouse forebrain,” European Journal of Neuroscience, vol. 26, no. 9, pp. 2473–2480, 2007. View at: Publisher Site | Google Scholar
  71. A. C. Granholm, D. Albeck, C. Bäckman et al., “A non-invasive system for delivering neural growth factors across the blood-brain barrier: a review,” Reviews in the Neurosciences, vol. 9, no. 1, pp. 31–55, 1998. View at: Google Scholar
  72. R. de Simone, E. Alleva, P. Tirassa, and L. Aloe, “Nerve growth factor released into the bloodstream following intraspecific fighting induces mast cell degranulation in adult male mice,” Brain, Behavior, and Immunity, vol. 4, no. 1, pp. 74–81, 1990. View at: Publisher Site | Google Scholar
  73. A. Leon, A. Buriani, R. D. Toso et al., “Mast cells synthesize, store, and release nerve growth factor,” Proceedings of the National Academy of Sciences of the United States of America, vol. 91, no. 9, pp. 3739–3743, 1994. View at: Google Scholar
  74. M. Torcia, L. Bracci-Laudiero, M. Lucibello et al., “Nerve growth factor is an autocrine survival factor for memory B lymphocytes,” Cell, vol. 85, no. 3, pp. 345–356, 1996. View at: Publisher Site | Google Scholar
  75. R. Levi-Montalcini, “The saga of the nerve growth factor,” NeuroReport, vol. 9, no. 16, pp. R71–R83, 1998. View at: Google Scholar
  76. W. C. Mobley, J. L. Rutkowski, G. I. Tennekoon, J. Gemski, K. Buchanan, and M. V. Johnston, “Nerve growth factor increases choline acetyltransferase activity in developing basal forebrain neurons,” Brain Research, vol. 387, no. 1, pp. 53–62, 1986. View at: Google Scholar
  77. W. Fischer, K. Wictorin, A. Bjorklund, L. R. Williams, S. Varon, and F. H. Gage, “Amelioration of cholinergic neuron atrophy and spatial memory impairment in aged rats by nerve growth factor,” Nature, vol. 328, no. 6134, pp. 65–68, 1987. View at: Google Scholar
  78. M. V. Sofroniew, C. L. Howe, and W. C. Mobley, “Nerve growth factor signaling, neuroprotection, and neural repair,” Annual Review of Neuroscience, vol. 24, pp. 1217–1281, 2001. View at: Publisher Site | Google Scholar
  79. H. Thoenen, “Neurotrophins and neuronal plasticity,” Science, vol. 270, no. 5236, pp. 593–598, 1995. View at: Google Scholar
  80. E. Castrén, “Neurotrophins as mediators of drug effects on mood, addiction, and neuroprotection,” Molecular Neurobiology, vol. 29, no. 3, pp. 289–301, 2004. View at: Publisher Site | Google Scholar
  81. E. Castrén, “Is mood chemistry?” Nature Reviews Neuroscience, vol. 6, no. 3, pp. 241–246, 2005. View at: Publisher Site | Google Scholar
  82. N. Berardi, T. Pizzorusso, and L. Maffei, “Critical periods during sensory development,” Current Opinion in Neurobiology, vol. 10, no. 1, pp. 138–145, 2000. View at: Publisher Site | Google Scholar
  83. J. Y. Hua and S. J. Smith, “Neural activity and the dynamics of central nervous system development,” Nature Neuroscience, vol. 7, no. 4, pp. 327–332, 2004. View at: Publisher Site | Google Scholar
  84. I. Branchi, I. D'Andrea, J. Sietzema et al., “Early social enrichment augments adult hippocampal BDNF levels and survival of BRDU-positive cells while increasing anxiety-and “depression”-like behavior,” Journal of Neuroscience Research, vol. 83, no. 6, pp. 965–973, 2006. View at: Publisher Site | Google Scholar
  85. I. D'Andrea, E. Alleva, and I. Branchi, “Communal nesting, an early social enrichment, affects social competences but not learning and memory abilities at adulthood,” Behavioural Brain Research, vol. 183, no. 1, pp. 60–66, 2007. View at: Publisher Site | Google Scholar
  86. M. Fiore, T. Amendola, V. Triaca, P. Tirassa, E. Alleva, and L. Aloe, “Agonistic encounters in aged male mouse potentiate the expression of endogenous brain NGF and BDNF: possible implication for brain progenitor cells' activation,” European Journal of Neuroscience, vol. 17, no. 7, pp. 1455–1464, 2003. View at: Publisher Site | Google Scholar
  87. R. M. Sapolsky, L. C. Krey, and B. S. McEwen, “The neuroendocrinology of stress and aging: the glucocorticoid cascade hypothesis,” Endocrine Reviews, vol. 7, no. 3, pp. 284–301, 1986. View at: Google Scholar
  88. R. M. Sapolsky, L. C. Krey, and B. S. McEwen, “Prolonged glucocorticoid exposure reduces hippocampal neuron number: implications for aging,” Journal of Neuroscience, vol. 5, no. 5, pp. 1222–1227, 1985. View at: Google Scholar
  89. L. Aloe, M. A. Tuveri, G. Guerra et al., “Changes in human plasma nerve growth factor level after chronic alcohol consumption and withdrawal,” Alcoholism: Clinical and Experimental Research, vol. 20, no. 3, pp. 462–465, 1996. View at: Google Scholar
  90. H. Selye, “A syndrome produced by diverse nocuous agents,” Nature, vol. 138, no. 3479, p. 32, 1936. View at: Google Scholar
  91. B. S. McEwen, “The neurobiology of stress: from serendipity to clinical relevance,” Brain Research, vol. 886, no. 1-2, pp. 172–189, 2000. View at: Publisher Site | Google Scholar
  92. B. Connor and M. Dragunow, “The role of neuronal growth factors in neurodegenerative disorders of the human brain,” Brain Research Reviews, vol. 27, no. 1, pp. 1–39, 1998. View at: Publisher Site | Google Scholar
  93. C. A. Altar, “Neurotrophins and depression,” Trends in Pharmacological Sciences, vol. 20, no. 2, pp. 59–61, 1999. View at: Publisher Site | Google Scholar
  94. E. Castrén, V. Võikar, and T. Rantamäki, “Role of neurotrophic factors in depression,” Current Opinion in Pharmacology, vol. 7, no. 1, pp. 18–21, 2007. View at: Publisher Site | Google Scholar
  95. R. S. Duman and L. M. Monteggia, “A neurotrophic model for stress-related mood disorders,” Biological Psychiatry, vol. 59, no. 12, pp. 1116–1127, 2006. View at: Publisher Site | Google Scholar
  96. S. Sen, R. Duman, and G. Sanacora, “Serum brain-derived neurotrophic factor, depression, and antidepressant medications: meta-analyses and implications,” Biological Psychiatry, vol. 64, no. 6, pp. 527–532, 2008. View at: Publisher Site | Google Scholar
  97. G. Bersani, A. Iannitelli, M. Fiore, F. Angelucci, and L. Aloe, “Data and hypotheses on the role of nerve growth factor and other neurotrophins in psychiatric disorders,” Medical Hypotheses, vol. 55, no. 3, pp. 199–207, 2000. View at: Publisher Site | Google Scholar
  98. J. Zubin and B. Spring, “Vulnerability. A new view of schizophrenia,” Journal of Abnormal Psychology, vol. 86, no. 2, pp. 103–126, 1977. View at: Publisher Site | Google Scholar
  99. Q. Yan, R. D. Rosenfeld, C. R. Matheson et al., “Expression of brain-derived neurotrophic factor protein in the adult rat central nervous system,” Neuroscience, vol. 78, no. 2, pp. 431–448, 1997. View at: Publisher Site | Google Scholar
  100. F. Cirulli, “Role of environmental factors on brain development and nerve growth factor expression,” Physiology and Behavior, vol. 73, no. 3, pp. 321–330, 2001. View at: Publisher Site | Google Scholar
  101. F. Cirulli, E. Alleva, A. Antonelli, and L. Aloe, “NGF expression in the developing rat brain: effects of maternal separation,” Developmental Brain Research, vol. 123, no. 2, pp. 129–134, 2000. View at: Publisher Site | Google Scholar
  102. F. Cirulli, N. Francia, A. Berry, L. Aloe, E. Alleva, and S. J. Suomi, “Early life stress as a risk factor for mental health: role of neurotrophins from rodents to non-human primates,” Neuroscience and Biobehavioral Reviews, vol. 33, no. 4, pp. 573–585, 2009. View at: Publisher Site | Google Scholar
  103. F. Cirulli, N. Francia, I. Branchi et al., “Changes in plasma levels of BDNF and NGF reveal a gender-selective vulnerability to early adversity in rhesus macaques,” Psychoneuroendocrinology, vol. 34, no. 2, pp. 172–180, 2009. View at: Publisher Site | Google Scholar
  104. F. Cirulli, A. Micera, E. Alleva, and L. Aloe, “Early maternal separation increases NGF expression in the developing rat hippocampus,” Pharmacology Biochemistry and Behavior, vol. 59, no. 4, pp. 853–858, 1998. View at: Publisher Site | Google Scholar
  105. T. M. Pham, S. Söderström, B. G. Henriksson, and A. H. Mohammed, “Effects of neonatal stimulation on later cognitive function and hippocampal nerve growth factor,” Behavioural Brain Research, vol. 86, no. 1, pp. 113–120, 1997. View at: Publisher Site | Google Scholar
  106. M. Roceri, F. Cirulli, C. Pessina, P. Peretto, G. Racagni, and M. A. Riva, “Postnatal repeated maternal deprivation produces age-dependent changes of brain-derived neurotrophic factor expression in selected rat brain regions,” Biological Psychiatry, vol. 55, no. 7, pp. 708–714, 2004. View at: Publisher Site | Google Scholar
  107. A. Sale, E. Putignano, L. Cancedda et al., “Enriched environment and acceleration of visual system development,” Neuropharmacology, vol. 47, no. 5, pp. 649–660, 2004. View at: Publisher Site | Google Scholar
  108. F. Cirulli, A. Berry, and E. Alleva, “Early disruption of the mother-infant relationship: effects on brain plasticity and implications for psychopathology,” Neuroscience and Biobehavioral Reviews, vol. 27, no. 1-2, pp. 73–82, 2003. View at: Publisher Site | Google Scholar
  109. L. X. Zhang, S. Levine, G. Dent et al., “Maternal deprivation increases cell death in the infant rat brain,” Developmental Brain Research, vol. 133, no. 1, pp. 1–11, 2002. View at: Publisher Site | Google Scholar
  110. C. P. Morgan and T. L. Bale, “Early prenatal stress epigenetically programs dysmasculinization in second-generation offspring via the paternal lineage,” Journal of Neuroscience, vol. 31, no. 33, pp. 11748–11755, 2011. View at: Publisher Site | Google Scholar
  111. C. Heim and C. B. Nemeroff, “The impact of early adverse experiences on brain systems involved in the pathophysiology of anxiety and affective disorders,” Biological Psychiatry, vol. 46, no. 11, pp. 1509–1522, 1999. View at: Publisher Site | Google Scholar
  112. C. Heim and C. B. Nemeroff, “The role of childhood trauma in the neurobiology of mood and anxiety disorders: preclinical and clinical studies,” Biological Psychiatry, vol. 49, no. 12, pp. 1023–1039, 2001. View at: Publisher Site | Google Scholar
  113. F. Holsboer, “The corticosteroid receptor hypothesis of depression,” Neuropsychopharmacology, vol. 23, no. 5, pp. 477–501, 2000. View at: Publisher Site | Google Scholar
  114. C. Crowley, S. D. Spencer, M. C. Nishimura et al., “Mice lacking nerve growth factor display perinatal loss of sensory and sympathetic neurons yet develop basal forebrain cholinergic neurons,” Cell, vol. 76, no. 6, pp. 1001–1011, 1994. View at: Publisher Site | Google Scholar
  115. S. Capsoni, G. Ugolini, A. Comparini, F. Ruberti, N. Berardi, and A. Cattaneo, “Alzheimer-like neurodegeneration in aged antinerve growth factor transgenic mice,” Proceedings of the National Academy of Sciences of the United States of America, vol. 97, no. 12, pp. 6826–6831, 2000. View at: Publisher Site | Google Scholar
  116. A. Nykjaer, R. Lee, K. K. Teng et al., “Sortilin is essential for proNGF-induced neuronal cell death,” Nature, vol. 427, no. 6977, pp. 843–848, 2004. View at: Publisher Site | Google Scholar
  117. S. Capsoni, C. Tiveron, D. Vignone, G. Amato, and A. Cattaneo, “Dissecting the involvement of tropomyosin-related kinase A and p75 neurotrophin receptor signaling in NGF deficit-induced neurodegeneration,” Proceedings of the National Academy of Sciences of the United States of America, vol. 107, no. 27, pp. 12299–12304, 2010. View at: Publisher Site | Google Scholar
  118. C. Matrone, A. P. M. Barbagallo, L. R. la Rosa et al., “APP is phosphorylated by TrkA and regulates NGF/TrkA signaling,” Journal of Neuroscience, vol. 31, no. 33, pp. 11756–11761, 2011. View at: Publisher Site | Google Scholar
  119. A. Chiaretti, A. Antonelli, R. Riccardi et al., “Nerve growth factor expression correlates with severity and outcome of traumatic brain injury in children,” European Journal of Paediatric Neurology, vol. 12, no. 3, pp. 195–204, 2008. View at: Publisher Site | Google Scholar
  120. A. Chiaretti, B. Falsini, L. Aloe, F. Pierri, C. Fantacci, and R. Riccardi, “Neuroprotective role of nerve growth factor in hypoxicischemic injury. From brain to skin,” Archives Italiennes de Biologie, vol. 149, no. 2, pp. 275–282, 2011. View at: Publisher Site | Google Scholar

Copyright © 2012 Alessandra Berry et al. This is an open access article distributed under the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.

More related articles

 PDF Download Citation Citation
 Download other formatsMore
 Order printed copiesOrder

Related articles

Article of the Year Award: Outstanding research contributions of 2020, as selected by our Chief Editors. Read the winning articles.